Unique strategy, novel technology.

We are transforming drug development to
radically expand the range of treatable cancers.

Most mutations are infrequent, understudied, and unaddressed — even on well-known oncogenes. As such, existing drugs target only the most common cancer-triggering mutations.

Our high-throughput, high-precision functional genomics approach opens up new therapeutic options for patients whose cancers are defined by the multitude of rarer cancer-triggering mutations that remain largely untreatable today.

The better we understand understudied mutations, the more patients we can reach. Here’s how.

Our Strategy: 4 steps to a paradigm shift
The foresight platform